189 related articles for article (PubMed ID: 18800152)
1. Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates.
Sakurai F; Nakamura SI; Akitomo K; Shibata H; Terao K; Kawabata K; Hayakawa T; Mizuguchi H
Gene Ther; 2009 Feb; 16(2):297-302. PubMed ID: 18800152
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35.
Sakurai F; Nakashima K; Yamaguchi T; Ichinose T; Kawabata K; Hayakawa T; Mizuguchi H
J Control Release; 2010 Dec; 148(2):212-8. PubMed ID: 20800630
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice.
Sakurai F; Kawabata K; Koizumi N; Inoue N; Okabe M; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2006 Jul; 13(14):1118-26. PubMed ID: 16541121
[TBL] [Abstract][Full Text] [Related]
4. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates.
Sakurai F; Nakamura S; Akitomo K; Shibata H; Terao K; Kawabata K; Hayakawa T; Mizuguchi H
Mol Ther; 2008 Apr; 16(4):726-33. PubMed ID: 18362928
[TBL] [Abstract][Full Text] [Related]
5. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector.
Sakurai F; Mizuguchi H; Hayakawa T
Gene Ther; 2003 Jun; 10(12):1041-8. PubMed ID: 12776162
[TBL] [Abstract][Full Text] [Related]
6. Transduction Properties of Adenovirus Serotype 35 Vectors After Intravenous Administration Into Nonhuman Primates.
Sakurai F; Nakamura SI; Akitomo K; Shibata H; Terao K; Kawabata K; Hayakawa T; Mizuguchi H
Mol Ther; 2008 Apr; 16(4):726-733. PubMed ID: 28178464
[TBL] [Abstract][Full Text] [Related]
7. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2005 Oct; 12(19):1424-33. PubMed ID: 15944730
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of human CD46 by adenovirus serotype 35 vectors.
Sakurai F; Akitomo K; Kawabata K; Hayakawa T; Mizuguchi H
Gene Ther; 2007 Jun; 14(11):912-9. PubMed ID: 17377598
[TBL] [Abstract][Full Text] [Related]
9. Long-term retinal transgene expression with FIV versus adenoviral vectors.
Loewen N; Leske DA; Cameron JD; Chen Y; Whitwam T; Simari RD; Teo WL; Fautsch MP; Poeschla EM; Holmes JM
Mol Vis; 2004 Apr; 10():272-80. PubMed ID: 15094709
[TBL] [Abstract][Full Text] [Related]
10. [Characterization of adenovirus serotype 35 vectors using genetically modified animals and non-human primates].
Sakurai F; Kawabata K; Mizuguchi H
Yakugaku Zasshi; 2006 Nov; 126(11):1013-9. PubMed ID: 17077607
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.
Ni S; Gaggar A; Di Paolo N; Li ZY; Liu Y; Strauss R; Sova P; Morihara J; Feng Q; Kiviat N; Touré P; Sow PS; Lieber A
Cancer Gene Ther; 2006 Dec; 13(12):1072-81. PubMed ID: 16874361
[TBL] [Abstract][Full Text] [Related]
12. Efficient gene delivery in human and rodent mast cells using adenovirus vectors.
Nakashima K; Sakurai F; Kawabata K; Mizuguchi H
J Control Release; 2008 Aug; 129(3):215-22. PubMed ID: 18572269
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35.
Sakurai F
Biol Pharm Bull; 2008 Oct; 31(10):1819-25. PubMed ID: 18827334
[TBL] [Abstract][Full Text] [Related]
14. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector.
Sakurai F; Mizuguchi H; Yamaguchi T; Hayakawa T
Mol Ther; 2003 Nov; 8(5):813-21. PubMed ID: 14599815
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated gene transfer into rat livers: comparative study of retrograde intrabiliary and antegrade intraportal administration.
Kuriyama S; Yoshiji H; Nakai S; Deguchi A; Uchida N; Kimura Y; Inoue H; Kinekawa F; Ogawa M; Nonomura T; Masaki T; Kurokohchi K; Watanabe S
Oncol Rep; 2005 Jan; 13(1):69-74. PubMed ID: 15583804
[TBL] [Abstract][Full Text] [Related]
16. Promoters influence the kinetics of transgene expression following adenovector gene delivery.
Chen P; Tian J; Kovesdi I; Bruder JT
J Gene Med; 2008 Feb; 10(2):123-31. PubMed ID: 18064718
[TBL] [Abstract][Full Text] [Related]
17. The short consensus repeats 1 and 2, not the cytoplasmic domain, of human CD46 are crucial for infection of subgroup B adenovirus serotype 35.
Sakurai F; Murakami S; Kawabata K; Okada N; Yamamoto A; Seya T; Hayakawa T; Mizuguchi H
J Control Release; 2006 Jul; 113(3):271-8. PubMed ID: 16790289
[TBL] [Abstract][Full Text] [Related]
18. In vivo transduction of cerebellar Purkinje cells using adeno-associated virus vectors.
Kaemmerer WF; Reddy RG; Warlick CA; Hartung SD; McIvor RS; Low WC
Mol Ther; 2000 Nov; 2(5):446-57. PubMed ID: 11082318
[TBL] [Abstract][Full Text] [Related]
19. Temporally regulated expression patterns following in utero adenovirus-mediated gene transfer.
Schachtner S; Buck C; Bergelson J; Baldwin H
Gene Ther; 1999 Jul; 6(7):1249-57. PubMed ID: 10455433
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution of a low dose of intravenously administered AAV-2, 10, and 11 vectors to cynomolgus monkeys.
Mori S; Takeuchi T; Enomoto Y; Kondo K; Sato K; Ono F; Iwata N; Sata T; Kanda T
Jpn J Infect Dis; 2006 Oct; 59(5):285-93. PubMed ID: 17060693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
